NorthWest Biotherapeutics Inc (NWBO)

[iwasadiver]

You’re failing to provide the nuance in your responses that would be a more accurate and true response;

Gilead announced the $11.9 Billion cash acquisition 2 months BEFORE approval for B-cell lymphomas refractory to standard treatment; and 2/3rds are cured by that standard treatment. Completely.

So your assertion that Kite was bought for the revenue of an approved drug is false. And Gilead payed $11.9 billion for a drug that had sales of $240 million in 2018.

At a cost of $373,000 per patient that means Gilead paid $11.9 billion for a drug that treated 659 people in 2018.

Maybe you’d like to re-address your correlation to a buyout price a few multiples of $11.9 billion for DCVax who’s potential is thousands of times greater than Yascarta? I think your analytical skills are a bit off kilter